Re: Abiraterone in metastatic prostate cancer without previous chemotherapy.

The use of abiraterone acetate plus prednisone in 1088 asymptomatic or mildly symptomatic patients with metastatic castration-resistant prostate cancer was associated with a statistically meaningful advantage in radiographic progression-free survival (PFS) versus placebo plusprednisone.